X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (535) 535
Publication (78) 78
Book / eBook (43) 43
Patent (23) 23
Video Recording (14) 14
Book Chapter (9) 9
Newspaper Article (7) 7
Book Review (5) 5
Conference Proceeding (5) 5
Magazine Article (5) 5
Dissertation (1) 1
Report (1) 1
Streaming Video (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (194) 194
index medicus (156) 156
male (141) 141
female (132) 132
middle aged (120) 120
adult (101) 101
aged (86) 86
hematology (75) 75
life sciences (64) 64
oncology (57) 57
cancer (49) 49
treatment outcome (44) 44
imatinib mesylate (42) 42
animals (38) 38
leukemia, myelogenous, chronic, bcr-abl positive - drug therapy (37) 37
aged, 80 and over (35) 35
prognosis (33) 33
chronic myeloid leukemia (32) 32
adolescent (31) 31
chronic myelogenous leukemia (31) 31
benzamides (30) 30
leukemia (30) 30
therapy (29) 29
hemic and lymphatic diseases (27) 27
abridged index medicus (26) 26
france (26) 26
antineoplastic combined chemotherapy protocols - therapeutic use (25) 25
chronic myeloid-leukemia (24) 24
disease-free survival (24) 24
pyrimidines - therapeutic use (24) 24
antineoplastic agents - therapeutic use (23) 23
biochemistry & molecular biology (23) 23
dasatinib (23) 23
imatinib (23) 23
young adult (23) 23
analysis (22) 22
pyrimidines - administration & dosage (22) 22
research (22) 22
mice (20) 20
cml (19) 19
human health and pathology (19) 19
mutation (19) 19
piperazines - administration & dosage (19) 19
leukemia, myelogenous, chronic, bcr-abl positive - genetics (18) 18
physics (18) 18
remission induction (18) 18
retrospective studies (18) 18
survival rate (18) 18
astronomy & astrophysics (17) 17
chemotherapy (17) 17
diagnosis (17) 17
lipids (17) 17
piperazines - therapeutic use (17) 17
prospective studies (17) 17
survival (17) 17
care and treatment (16) 16
child (16) 16
patients (16) 16
protein kinase inhibitors - therapeutic use (16) 16
pyrimidines - adverse effects (16) 16
risk factors (16) 16
tyrosine (16) 16
astrophysics (15) 15
disease (15) 15
follow-up (15) 15
follow-up studies (15) 15
genetic aspects (15) 15
leukemia, myelogenous, chronic, bcr-abl positive - pathology (15) 15
minimal residual disease (15) 15
amyotrophic lateral sclerosis (14) 14
efficacy (14) 14
history (14) 14
metabolism (14) 14
recurrence (14) 14
risk (14) 14
[sdv.can]life sciences [q-bio]/cancer (13) 13
antineoplastic agents (13) 13
apoptosis (13) 13
cell biology (13) 13
cholesterol (13) 13
cohort studies (13) 13
hematology, oncology and palliative medicine (13) 13
human necessities (13) 13
hygiene (13) 13
in-vitro (13) 13
leukemia, myeloid, acute - drug therapy (13) 13
medical or veterinary science (13) 13
medicine (13) 13
physiological aspects (13) 13
piperazines - adverse effects (13) 13
preparations for medical, dental, or toilet purposes (13) 13
rats (13) 13
time factors (13) 13
tyrosine kinase inhibitor (13) 13
antineoplastic agents - adverse effects (12) 12
bcr-abl (12) 12
cells (12) 12
cytarabine - administration & dosage (12) 12
expression (12) 12
fusion proteins, bcr-abl - genetics (12) 12
more...
Library Location Library Location
Library Location Library Location
X
Sort by Item Count (A-Z)
Filter by Count
Robarts - Stacks (19) 19
Media Commons - Audio Visual (13) 13
UTL at Downsview - May be requested (9) 9
Collection Dvlpm't (Acquisitions) - Vendor file (5) 5
Gerstein Science - Stacks (3) 3
Music - Stacks (3) 3
St. Michael's College (John M. Kelly) - 2nd Floor (3) 3
Robarts - May be requested in 6-10 wks (2) 2
St. Michael's College (John M. Kelly) - Audio Visual (2) 2
UofT at Scarborough - Stacks (2) 2
Victoria University CRRS - Library use only (2) 2
Collection Dvlpm't (Acquisitions) - Closed Orders (1) 1
Engineering & Comp. Sci. - Stacks (1) 1
Media Commons - Library or classroom use (1) 1
Online Resources - Online (1) 1
Regis College - Storage (1) 1
Robarts - Storage (1) 1
St. Michael's College (John M. Kelly) - 3rd Floor (1) 1
Thomas Fisher Rare Book - May be requested at Fisher (1) 1
UTL at Downsview - In process for Downsview (1) 1
University College (Laidlaw) - Stacks (1) 1
UofT Schools - Special Collections (1) 1
UofT at Mississauga - Stacks (1) 1
Victoria University E.J. Pratt - Reference (1) 1
Victoria University E.J. Pratt - Riese (1) 1
Victoria University E.J. Pratt - Stacks (1) 1
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (535) 535
French (128) 128
Spanish (9) 9
German (7) 7
Portuguese (4) 4
Danish (2) 2
Chinese (1) 1
Czech (1) 1
Italian (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Leukemia & Lymphoma, ISSN 1042-8194, 12/2018, Volume 59, Issue 12, pp. 2782 - 2791
Chronic myeloid leukemia is the first example of successful clinical use of tyrosine kinase inhibitors (TKIs). Blockade of oncogenic BCR-ABL1 tyrosine kinase... 
tyrosine kinase inhibitors | Chronic myeloid leukemia | deep molecular response | discontinuation | CHRONIC MYELOGENOUS LEUKEMIA | TREATMENT-FREE REMISSION | COMPLETE MOLECULAR REMISSION | IMATINIB DISCONTINUATION | FOLLOW-UP | CHRONIC MYELOID-LEUKEMIA | PREGNANCY | CESSATION | ONCOLOGY | HEMATOLOGY | CML PATIENTS | FRONTLINE NILOTINIB
Journal Article
Lancet Oncology, The, ISSN 1470-2045, 2010, Volume 11, Issue 11, pp. 1029 - 1035
Journal Article
Lancet, The, ISSN 0140-6736, 2012, Volume 379, Issue 9825, pp. 1508 - 1516
Journal Article
5e ed. rev., corr. et augm., ISBN 2903911495, 143
Book
The New England Journal of Medicine, ISSN 0028-4793, 12/2006, Volume 355, Issue 23, pp. 2408 - 2417
The constitutively active BCR-ABL tyrosine kinase is the cause of chronic myeloid leukemia. Imatinib is the first small synthetic molecular inhibitor of the... 
CHRONIC MYELOGENOUS LEUKEMIA | CELLS | MEDICINE, GENERAL & INTERNAL | CHRONIC GRANULOCYTIC-LEUKEMIA | INTERFERON-ALPHA | CHRONIC-PHASE | ABL TYROSINE KINASE | COMPLETE CYTOGENETIC REMISSION | PHILADELPHIA-CHROMOSOME | BLAST CRISIS | ALPHA PLUS CYTARABINE | Follow-Up Studies | Humans | Leukemia, Myelogenous, Chronic, BCR-ABL Positive - drug therapy | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Male | Antineoplastic Agents - therapeutic use | Antineoplastic Agents - adverse effects | Fusion Proteins, bcr-abl - blood | Female | Leukemia, Myelogenous, Chronic, BCR-ABL Positive - mortality | Kaplan-Meier Estimate | Survival Rate | Treatment Outcome | Piperazines - therapeutic use | Imatinib Mesylate | Piperazines - adverse effects | Cytarabine - administration & dosage | Interferon-alpha - administration & dosage | Disease-Free Survival | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Pyrimidines - therapeutic use | Pyrimidines - adverse effects | Survival Analysis | Benzamides | Protein-Tyrosine Kinases - antagonists & inhibitors | Dosage and administration | Chronic myeloid leukemia | Drug therapy | Interferon alpha | Clinical trials | Bone marrow | Transplants & implants | Pharmaceutical industry | Leukemia | Medical and Health Sciences | MEDICINE | Medicin och hälsovetenskap | MEDICIN
Journal Article
Journal of Clinical Oncology, ISSN 0732-183X, 02/2014, Volume 32, Issue 5, pp. 424 - 430
Journal Article
Leukemia, ISSN 0887-6924, 08/2018, Volume 32, Issue 8, pp. 1768 - 1777
Journal Article
Journal of Clinical Investigation, ISSN 0021-9738, 09/2016, Volume 126, Issue 9, pp. 3207 - 3218
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 12/2010, Volume 363, Issue 26, pp. 2511 - 2521
In this study, adding pegylated interferon alfa-2a to imatinib therapy for chronic myeloid leukemia resulted in a greater reduction in the number of cells... 
CHRONIC MYELOGENOUS LEUKEMIA | CHROMOSOME | MEDICINE, GENERAL & INTERNAL | INTERFERON | CML | ABL TYROSINE KINASE | HEMATOPOIETIC STEM-CELLS | FOLLOW-UP | PATIENTS RECEIVING IMATINIB | QUIESCENT | CYTARABINE | Piperazines - administration & dosage | Humans | Leukemia, Myeloid, Chronic-Phase - pathology | Middle Aged | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Polyethylene Glycols - adverse effects | Male | Proto-Oncogene Proteins c-abl - analysis | Cytarabine - adverse effects | Recombinant Proteins | RNA, Neoplasm - analysis | Adult | Female | Transcription, Genetic | Neutropenia - chemically induced | Proto-Oncogene Proteins c-abl - genetics | Pyrimidines - administration & dosage | Leukemia, Myeloid, Chronic-Phase - drug therapy | Anemia - chemically induced | Treatment Outcome | Thrombocytopenia - chemically induced | Imatinib Mesylate | Piperazines - adverse effects | Remission Induction | Cytarabine - administration & dosage | Polyethylene Glycols - administration & dosage | Interferon-alpha - administration & dosage | Leukemia, Myeloid, Chronic-Phase - mortality | Fusion Proteins, bcr-abl - genetics | Fusion Proteins, bcr-abl - analysis | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Pyrimidines - adverse effects | Survival Analysis | Stem Cells - drug effects | Interferon-alpha - adverse effects | Benzamides | Drug therapy | Chronic myeloid leukemia | Medical research | Kinases | Leukemia | Manuscripts
Journal Article